Bringing the next evolution of medicine
to market
Osiris Therapeutics, Inc. is committed to developing its proprietary adult stem cell technology in order to provide physicians with next-generation tools for the treatment and functional restoration of damaged or diseased tissues. The multi-potential character of our stem cell product candidates provides the basis for a cell therapy platform that represents a virtually limitless number of indications.
Osiris Therapeutics currently has three development phase products, all of which are in
clinical trials. The platform covers product indications in a diverse range of medical specialties, including inflammatory, cardiology and orthopedics.
Prochymal™ is currently enrolling patients in a clinical trial for the treatment of steroid-refractory acute Graft vs. Host Disease (GVHD). GVHD is a life threatening immune condition that affects a large percentage of patients who have received a bone marrow transplant.
Prochymal™ is also being evaluated in clinical trials for the treatment of Crohn's disease, a painful inflammatory bowel disease which can lead to disability and surgery. Enrollment for this trial has been completed.
Prochymal™ is currently in Phase III clinical trials for the treatment of GvHD and Crohn’s Disease and has demonstrated preliminary efficacy in the treatment of patients experiencing first-time heart attacks. These trials have shown Prochymal’s potential to reverse cellular damage and improve survival in disease states similar to
ARS.
Chondrogen™ is currently being evaluated in clinical trials for regeneration of the meniscus in the knee, and prevention of osteoarthritis. Enrollment for this trial has been completed.
In addition to these medical conditions in clinical trials, Osiris has one product currently on the market. This product, Osteocel
®, is the first biologic product to provide all three bone growth properties: osteoconduction, osteoinduction, and osteogenesis, allowing orthopedic surgeons to provide their patients with bone growth conditions without the discomfort
and complications of autograft harvesting.
Osiris is continuing to research possible applications of its technology for use in new indications.
